Research & Development Research & Development
Pipeline

Cascade Pharmaceuticals emphasizes originality and focuses on differentiated innovation in drug development. The company is actively advancing multiple drug candidates targeting over 10 distinct targets. By adhering to first principles of drug development and aligning with the body's natural physiological rhythms, the team has successfully developed Linafexor, a first-in-class FXR agonist, and Thybetaxor, a potential best-in-class thyroid hormone receptor β (THRβ) agonist.

Program
Targets
Molecule Type
Indication
Preclinical
IND
Phase I
Phase II
Phase III
NDA
Rights
CS0159
(Linafexor)
FXRsmall moleculeMASH

Global
PBC

Global
PSC

Global
IBD

Global

Obesity

(Combo with GLP1RA)

Global
CS060380THRβsmall moleculeMASH

Global
CS12****GLP1R/GIPR/GCGRsmall moleculeObesity

Global
T2DM

Global
CS14****GLP1R/GIPR/GCGRpeptideObesity

Global
T2DM

Global
© 2020 Cascade Pharmaceuticals, Inc All Rights Reserved. ICP备案 沪ICP备88888888号